|

GVA + HDAC Consolidation & Gilteritinib Maintenance Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • First Affiliated Hospital of Zhejiang University1

Indications

  • Fit Patients1
  • Intermediate Risk Acute Myeloid Leukemia1
  • FLT3 Internal Tandem Duplication Positive1
  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.